Wedbush downgraded Kinnate Biopharma to Neutral from Outperform with a price target of $2, down from $14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KNTE:
- Kinnate Biopharma downgraded to Neutral on uncertainty at Piper Sandler
- Kinnate Biopharma downgraded to Neutral from Overweight at Piper Sandler
- Kinnate Biopharma trading resumes
- Kinnate Biopharma to reduce workforce by 70%, announces reprioritization plan
- Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring